Detalles de la búsqueda
1.
CNX-012-570, a direct AMPK activator provides strong glycemic and lipid control along with significant reduction in body weight; studies from both diet-induced obese mice and db/db mice models.
Cardiovasc Diabetol
; 13: 27, 2014 Jan 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-24460834
2.
CNX-011-67, a novel GPR40 agonist, enhances glucose responsiveness, insulin secretion and islet insulin content in n-STZ rats and in islets from type 2 diabetic patients.
BMC Pharmacol Toxicol
; 15: 19, 2014 Mar 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-24666736
3.
A novel 11ß-hydroxysteroid dehydrogenase type1 inhibitor CNX-010-49 improves hyperglycemia, lipid profile and reduces body weight in diet induced obese C57B6/J mice with a potential to provide cardio protective benefits.
BMC Pharmacol Toxicol
; 15: 43, 2014 Aug 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-25098735
4.
CNX-013-B2, a unique pan tissue acting rexinoid, modulates several nuclear receptors and controls multiple risk factors of the metabolic syndrome without risk of hypertriglyceridemia, hepatomegaly and body weight gain in animal models.
Diabetol Metab Syndr
; 6(1): 83, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25143786
5.
Treatment with CNX-011-67, a novel GPR40 agonist, delays onset and progression of diabetes and improves beta cell preservation and function in male ZDF rats.
BMC Pharmacol Toxicol
; 14: 28, 2013 May 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-23692921
Resultados
1 -
5
de 5
1
Próxima >
>>